Angelica Loskog

Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial

Hahn, Amanda; Irenaeus, Sandra; Sandin, Linda C.; Nordström, Clara et al.

Ingår i Clinical Cancer Research, s. 3157-3168, 2026

• DOI för Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial

LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

Hamid, O.; Ekström-Rydén, Viktoria; Mehmi, I.; Wang, D. et al.

Ingår i Nature Communications, 2026

• DOI för LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
• Ladda ner fulltext (pdf) av LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

Grauers Wiktorin, Hanna; Rydén, Viktoria; Ek, Ida; Eriksson, Emma et al.

Ingår i Biomarker Research, 2026

• DOI för Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
• Ladda ner fulltext (pdf) av Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

Efficacy of mebendazole in the spontaneous NZBxNZWF1 animal model of systemic lupus erythematosus

Eloranta, Maija-Leena; Nygren, Peter; Larsson, Rolf; Loskog, Angelica et al.

Ingår i Scientific Reports, 2026

• DOI för Efficacy of mebendazole in the spontaneous NZBxNZWF1 animal model of systemic lupus erythematosus
• Ladda ner fulltext (pdf) av Efficacy of mebendazole in the spontaneous NZBxNZWF1 animal model of systemic lupus erythematosus

CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

Naseri, Sedigheh; Mejia Cordova, Mariela; Wenthe, Jessica; Lövgren, Tanja et al.

Ingår i Journal of Cellular and Molecular Medicine, 2024

• DOI för CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling
• Ladda ner fulltext (pdf) av CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial

Hahn, Amanda; Irenaeus, Sandra; Sandin, Linda C.; Nordström, Clara et al.

Ingår i Clinical Cancer Research, s. 3157-3168, 2026

• DOI för Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial

LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

Hamid, O.; Ekström-Rydén, Viktoria; Mehmi, I.; Wang, D. et al.

Ingår i Nature Communications, 2026

• DOI för LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
• Ladda ner fulltext (pdf) av LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

Grauers Wiktorin, Hanna; Rydén, Viktoria; Ek, Ida; Eriksson, Emma et al.

Ingår i Biomarker Research, 2026

• DOI för Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
• Ladda ner fulltext (pdf) av Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

Efficacy of mebendazole in the spontaneous NZBxNZWF1 animal model of systemic lupus erythematosus

Eloranta, Maija-Leena; Nygren, Peter; Larsson, Rolf; Loskog, Angelica et al.

Ingår i Scientific Reports, 2026

• DOI för Efficacy of mebendazole in the spontaneous NZBxNZWF1 animal model of systemic lupus erythematosus
• Ladda ner fulltext (pdf) av Efficacy of mebendazole in the spontaneous NZBxNZWF1 animal model of systemic lupus erythematosus

CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

Naseri, Sedigheh; Mejia Cordova, Mariela; Wenthe, Jessica; Lövgren, Tanja et al.

Ingår i Journal of Cellular and Molecular Medicine, 2024

• DOI för CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling
• Ladda ner fulltext (pdf) av CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Musher, Benjamin L.; Rowinsky, Eric K.; Smaglo, Brandon G.; Abidi, Wasif et al.

Ingår i The Lancet Oncology, s. 488-500, 2024

• DOI för LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Ingår i Journal of Translational Medicine, 2023

• DOI för Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
• Ladda ner fulltext (pdf) av Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients

Sarén, Tina; Ramachandran, Mohanraj; Gammelgård, Gustav; Lövgren, Tanja et al.

Ingår i Clinical Cancer Research, s. 4139-4152, 2023

• DOI för Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients
• Ladda ner fulltext (pdf) av Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients

The signaling and the metabolic differences of various CAR T cell designs

Razavi, Azadeh Sadat; Loskog, Angelica S.; Razi, Sepideh; Rezaei, Nima

Ingår i International Immunopharmacology, 2023

• DOI för The signaling and the metabolic differences of various CAR T cell designs

Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis

Hellström, Vivan; Tufveson, Gunnar; Loskog, Angelica; Bengtsson, Mats et al.

Ingår i PLOS ONE, 2022

• DOI för Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
• Ladda ner fulltext (pdf) av Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Ingår i MOLECULAR THERAPY-ONCOLYTICS, s. 429-442, 2022

• DOI för Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
• Ladda ner fulltext (pdf) av Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

Sjöholm, Therese; Korenyushkin, Alexander; Gammelgård, Gustav; Sarén, Tina et al.

Ingår i Cancer Imaging, 2022

• DOI för Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
• Ladda ner fulltext (pdf) av Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Mansoori, Sharmineh; Fryknäs, Mårten; Alvfors, Carina; Loskog, Angelica et al.

Ingår i Scientific Reports, 2021

• DOI för A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
• Ladda ner fulltext (pdf) av A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes

Labani-Motlagh, Alireza; Naseri, Sedigheh; Wenthe, Jessica; Eriksson, Emma et al.

Ingår i MOLECULAR THERAPY-ONCOLYTICS, s. 508-518, 2021

• DOI för Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
• Ladda ner fulltext (pdf) av Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes

Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up

Saellstrom, Sara; Sadeghi, Arian; Eriksson, Emma; Segall, Thomas et al.

Ingår i Frontiers in Veterinary Science, 2021

• DOI för Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up
• Ladda ner fulltext (pdf) av Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

Wenthe, Jessica; Naseri, Sedigheh; Labani-Motlagh, Alireza; Enblad, Gunilla et al.

Ingår i Cancer Immunology and Immunotherapy, s. 2851-2865, 2021

• DOI för Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
• Ladda ner fulltext (pdf) av Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Irenaeus, Sandra; Hellström, Vivan; Wenthe, Jessica; Krause, Johan et al.

Ingår i Cancer Gene Therapy, s. 1188-1197, 2021

• DOI för Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Jernberg Wiklund, Helena et al.

Ingår i Cancer Gene Therapy, s. 948-959, 2020

• DOI för Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
• Ladda ner fulltext (pdf) av Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40

Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Andersson, Claes; Selvin, Tove; Blom, Kristin; Rubin, Jenny et al.

Ingår i Scientific Reports, 2020

• DOI för Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
• Ladda ner fulltext (pdf) av Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.

Rowinsky, Eric K; Paner, Agne; Berdeja, Jesus G; Paba-Prada, Claudia et al.

Ingår i Investigational new drugs, s. 1448-1453, 2020

• DOI för Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients

Schiza, Aglaia; Irenaeus, Sandra; Ortiz-Nieto, Francisco; Loskog, Angelica S. et al.

Ingår i Scientific Reports, 2019

• DOI för Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
• Ladda ner fulltext (pdf) av Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients

Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients

Amini, Rose-Marie; Enblad, Gunilla; Hollander, Peter; Laszlo, S. et al.

Ingår i BMC Cancer, 2019

• DOI för Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients
• Ladda ner fulltext (pdf) av Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Blom, Kristin; Eriksson, Jenny; Berglund, Malin; Jarvius, Malin et al.

Ingår i BMC Research Notes, 2019

• DOI för Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
• Ladda ner fulltext (pdf) av Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-beta, Collagen Type I, and PD-L1/PD-1

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Ingår i Journal of Immunology, s. 787-798, 2019

• DOI för IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-beta, Collagen Type I, and PD-L1/PD-1

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

Hoffmann, Jean-Marc; Schubert, Maria-Luisa; Wang, Lei; Hueckelhoven, Angela et al.

Ingår i Frontiers in Immunology, 2018

• DOI för Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
• Ladda ner fulltext (pdf) av Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome

Hollander, Peter; Rostgaard, Klaus; Ekström-Smedby, Karin; Molin, Daniel et al.

Ingår i European Journal of Haematology, s. 88-97, 2018

• DOI för An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
• Ladda ner fulltext (pdf) av An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

Enblad, Gunilla; Karlsson, Hannah; Gammelgård, Gustav; Wenthe, Jessica et al.

Ingår i Clinical Cancer Research, s. 6185-6194, 2018

• DOI för A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

Immunostimulatory gene therapy enhances PD-1 blockade antibody therapy in experimental lung cancer

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Loskog, Angelica S.

Ingår i CANCER IMMUNOLOGY RESEARCH, 2018

• DOI för Immunostimulatory gene therapy enhances PD-1 blockade antibody therapy in experimental lung cancer

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Svensson, Emma et al.

Ingår i Journal of Translational Medicine, 2017

• DOI för Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
• Ladda ner fulltext (pdf) av Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Irenaeus, Sandra; Schiza, Aglaia; Mangsbo, Sara M.; Wenthe, Jessica et al.

Ingår i Oncotarget, s. 78573-78587, 2017

• DOI för Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
• Ladda ner fulltext (pdf) av Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

An oncolytic virus targeting desmoplasia and immune activation in pancreatic cancer

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Ingår i Scandinavian Journal of Immunology, s. 335-335, 2017

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Svensson, Emma; Milenova, Ioanna; Wenthe, Jessica; Ståhle, Magnus et al.

Ingår i Clinical Cancer Research, s. 5846-5857, 2017

• DOI för Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Distinct phenotype of CD19-specific CAR T cells generated from healthy donor vs. patient lymphocytes using either IL-7/IL-15 or IL-2

Hoffmann, J. -M; Stock, S.; Sellner, L.; Hueckelhoven, A. et al.

Ingår i Oncology Research and Treatment, s. 213-213, 2017

Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer

Yu, Di; Leja, Justyna; Loskog, Angelica S.; Hellman, Per et al.

Ingår i Neuroendocrinology, s. 54-66, 2017

• DOI för Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer

Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Eriksson, Emma et al.

Ingår i Scandinavian Journal of Immunology, s. 337-337, 2017

Immunological biomarkers correlate to survival in CAR19-treated patients

Lövgren, Tanja; Wenthe, Jessica; Karlsson, S. C. Hannah; Gammelgård, Gustav et al.

Ingår i Scandinavian Journal of Immunology, s. 337-337, 2017

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Kaartinen, Tanja; Luostarinen, Annu; Maliniemi, Pilvi; Keto, Joni et al.

Ingår i Cytotherapy, s. 689-702, 2017

• DOI för Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion
• Ladda ner fulltext (pdf) av Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

Hellström, Vivan; Tufveson, Gunnar; Wallgren, AnnaCarin; Loskog, Angelica et al.

Ingår i American Journal of Transplantation, s. 472-472, 2017

• DOI för Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Blom, Kristin; Senkowski, Wojciech; Jarvius, Malin; Berglund, Malin et al.

Ingår i Immunopharmacology and immunotoxicology, s. 199-210, 2017

• DOI för The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Activating CD40 While Inhibiting IL6R Induces Cytokine Production without PDL1 Upregulation in DCs

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Ingår i Molecular Therapy, s. 54-54, 2017

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Eriksson, Emma; Moreno, R; Milenova, I. Yoanna; Liljenfeldt, L et al.

Ingår i Gene Therapy, s. 92-103, 2017

• DOI för Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
• Ladda ner fulltext (pdf) av Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Low il-2 concentration favors generation of early memory t cells over terminal eefectors during car t-cell expansion

Luostarinen, A.; Kaartinen, T.; Maliniernii, P.; Keto, J. et al.

Ingår i Cytotherapy, 2017

• DOI för Low il-2 concentration favors generation of early memory t cells over terminal eefectors during car t-cell expansion

Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Eriksson, Emma; Wenthe, Jessica; Irenaeus, Sandra; Loskog, Angelica et al.

Ingår i Journal of Translational Medicine, 2016

• DOI för Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer
• Ladda ner fulltext (pdf) av Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik et al.

Ingår i Leukemia Research, s. 95-103, 2016

• DOI för Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

An Oncolytic Adenovirus Gene Therapy Targeting Both Tumor Cell Survival and Desmoplasia in Pancreatic Cancer

Milenova, Ioanna; Eriksson, Emma; Moreno, Rafael; Alemany, Ramon et al.

Ingår i Molecular Therapy, 2016

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Ingår i British Journal of Cancer, s. 872-880, 2016

• DOI för Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

Plasma Proteomics In Chronic Myeloid Leukemia Patients Before And After Initiation Of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity And Loss Of Angiogenic Stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, H. et al.

Ingår i Haematologica, s. 730-730, 2016

A Novel Oncolytic Adenovirus Expressing Tumor Microenvironment Stimulators to Evoke and Facilitate Anti-Tumor Immune Responses

Wenthe, Jessica; Eriksson, Emma; Milenova, Ioanna; Moreno, Rafael et al.

Ingår i Molecular Therapy, 2016

T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells

Hoffmann, J. -M; Gern, U.; Wang, L.; Kleist, C. et al.

Ingår i Oncology Research and Treatment, s. 136-136, 2016

• DOI för T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells

CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia: report from the Swedish phase Ulla trial

Enblad, Gunilla; Karlsson, Hannah; Wikström, Kristina I.; Essand, Magnus et al.

Ingår i CANCER IMMUNOLOGY RESEARCH, 2016

• DOI för CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia: report from the Swedish phase Ulla trial

A Clinical Trial Using Third Generation CD19 Targeting CAR T Cells for Relapsed Lymphoma and Leukemia

Enblad, Gunilla; Karlsson, Hannah; Wenthe, Jessica; Wikström, Kristina I. et al.

Ingår i Molecular Therapy, 2016

Prognostic Implications Of An Active, Innate Or Anergic Immune Response In The Hodgkin Lymphoma Tumor Microenvironment

Hollander, Peter; Rostgaard, K.; Smedby, K. E.; Molin, Daniel et al.

Ingår i Haematologica, s. 3-3, 2016

CD40L/4-1BBL-expressing oncolytic adenovirus (LOAd703) stimulates human dendritic cell production of Th1 cytokines and antigen-specific T cells

Svensson, Emma; Milenova, I. Yoanna; Moreno, R.; Alemany, R. et al.

Ingår i Human Gene Therapy, 2015

CD40L and 4-1BBL immunostimulating gene therapy reduces myeloid-derived suppressor cells (MDSCs) while promoting T and NK cell activation

Svensson, Emma; Wenthe, Jessica; Milenova, I. Yoanna; Moreno, R. et al.

Ingår i Human Gene Therapy, 2015

Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles

Loskog, Angelica

Ingår i Viruses, s. 5780-5791, 2015

• DOI för Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles
• Ladda ner fulltext (pdf) av Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

Karlsson, Hannah; Svensson, Emma; Gigg, Camilla; Jarvius, Malin et al.

Ingår i PLOS ONE, 2015

• DOI för Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors
• Ladda ner fulltext (pdf) av Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

Immunotherapy with a CD40L/4-1BBL double-armed oncolytic adenovirus drives Th1 immunity and control tumor progression in a pancreas cancer model

Svensson, Emma; Milenova, Ioanna; Moreno, Rafael; Alemany, Ramon et al.

Ingår i Cancer Research, 2015

• DOI för Immunotherapy with a CD40L/4-1BBL double-armed oncolytic adenovirus drives Th1 immunity and control tumor progression in a pancreas cancer model

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Christiansson, Lisa; Söderlund, Stina; Mangsbo, Sara; Hjorth-Hansen, Henrik et al.

Ingår i Molecular Cancer Therapeutics, s. 1181-1191, 2015

• DOI för The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation

Huang, Hua; Langenkamp, Elise; Georganaki, Maria; Loskog, Angelica et al.

Ingår i The FASEB Journal, s. 227-238, 2015

• DOI för VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation

Increased TACE (Tumor necrosis factor-alpha +/--converting enzyme; ADAM17) Activity Associates with Decreased CD62L Expression, Increased Soluble CD62L Plasma Levels and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP): Results from an ENEST1st Substudy

Sopper, Sieghart; Mustjoki, Satu; Loskog, Angelica; Gjertsen, Bjorn T. et al.

Ingår i Blood, 2015

Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity

Rodriguez-Garcia, A.; Svensson, Emma; Gil-Hoyos, R.; Fajardo, C. A. et al.

Ingår i Gene Therapy, s. 596-601, 2015

• DOI för Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity

Third Generation CD19-CAR T Cells for Relapsed and Refractory Lymphoma and Leukemia Report from the Swedish Phase I/IIa Trial

Enblad, Gunilla; Karlsson, Hannah; Wikström, Kristina; Essand, Magnus et al.

Ingår i Blood, 2015

Development of Gene Transfer Technology

Svensson, Emma; Moreno, R.; Milenova, Ioanna; Christiansson, Lisa et al.

Ingår i Human Gene Therapy, 2014

AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Ingår i Molecular Therapy, 2014

• DOI för AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Christiansson, Lisa; Mustjoki, Satu; Simonsson, Bengt; Olsson-Strömberg, Ulla et al.

Ingår i EuPA Open Proteomics, s. 37-47, 2014

• DOI för The use of multiplex platforms for absolute and relative protein quantification of clinical material

CD62L Expression on T Cells is Decreased in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Predicts Response to Therapy with Frontline Nilotinib

Sopper, S.; Mustjoki, S.; Loskog, Angelica; Gjertsen, B. et al.

Ingår i Haematologica, s. 64-64, 2014

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Sandin, Linda C.; Eriksson, Fredrik; Ellmark, Peter; Loskog, Angelica S. I. et al.

Ingår i Oncoimmunology, 2014

• DOI för Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Immunostimulating Gene Therapy Using an Oncolytic Adenovirus Armed with CD40 Ligand Potently Kill Tumor Cells, Activates Dendritic Cells and Induces T Cell Responses

Svensson, Emma; Moreno, Rafael; Milenova, Ioanna; Christiansson, Lisa et al.

Ingår i Molecular Therapy, 2014

Antigen Signaling Enhances Proliferation and Cytotoxic Capacity of CD19-Targeting CD28/4-1BB CAR T Cells During Expansion Without Inducing Exhaustion

Karlsson, Hannah; Gigg, Camilla; Svensson, Emma; Larsson, Rolf et al.

Ingår i Molecular Therapy, 2014

Intranasal Delivery of CNS-Retargeted Human Mesenchymal Stromal Cells Prolongs Treatment Efficacy of Experimental Autoimmune Encephalomyelitis

Fransson, Moa; Piras, Elena; Wang, Hao; Burman, Joachim et al.

Ingår i Immunology, s. 431-441, 2014

• DOI för Intranasal Delivery of CNS-Retargeted Human Mesenchymal Stromal Cells Prolongs Treatment Efficacy of Experimental Autoimmune Encephalomyelitis

Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis

Burman, Joachim; Svensson, Emma; Fransson, Moa; Loskog, Angelica et al.

Ingår i Journal of Neuroimmunology, s. 141-141, 2014

• DOI för Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis

CAR T Cells Express CD40L and Activates Human Dendritic Cells

Karlsson, Hannah; Gustafsson, Wictor; Olsson-Strömberg, Ulla; Savoldo, Barbara et al.

Ingår i Molecular Therapy, 2014

Assessing tissue damage in multiple sclerosis: a biomarker approach

Burman, Joachim; Zetterberg, H; Fransson, Moa; Loskog, Angelica SI. et al.

Ingår i Acta Neurologica Scandinavica, s. 81-89, 2014

• DOI för Assessing tissue damage in multiple sclerosis: a biomarker approach

Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand

Liljenfeldt, Lina; Gkirtzimanaki, Katerina; Vyrla, Dimitra; Svensson, Emma et al.

Ingår i Cancer Immunology and Immunotherapy, s. 273-282, 2014

• DOI för Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand

The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention

Burman, Joachim; Svensson, Emma; Fransson, Moa; Loskog, Angelica S I et al.

Ingår i Journal of Neuroimmunology, s. 153-159, 2014

• DOI för The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention

CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

Liljenfeldt, Lina; Dieterich, Lothar C.; Dimberg, Anna; Mangsbo, Sara M. et al.

Ingår i Cancer Gene Therapy, s. 95-102, 2014

• DOI för CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

Reduced Expression of CD62L Is Associated with Increased ADAM1 7 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Sopper, Sieghart; Mustjoki, Satu; Loskog, Angelica; Gjertsen, Bjorn T. et al.

Ingår i Blood, 2014

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Christiansson, Lisa; Söderlund, Stina; Svensson, Emma; Mustjoki, Satu et al.

Ingår i PLOS ONE, 2013

• DOI för Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
• Ladda ner fulltext (pdf) av Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

alpha B-Crystallin regulates expansion of CD11b(+)Gr-1(+) immature myeloid cells during tumor progression

Dieterich, Lothar C; Schiller, Petter; Huang, Hua; Wawrousek, Eric F et al.

Ingår i The FASEB Journal, s. 151-162, 2013

• DOI för alpha B-Crystallin regulates expansion of CD11b(+)Gr-1(+) immature myeloid cells during tumor progression

T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis

Burman, Joachim; Fransson, Moa; Tötterman, Thomas H.; Fagius, Jan et al.

Ingår i Immunology, s. 211-219, 2013

• DOI för T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis

Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma

Westberg, Sara; Sadeghi, Arian; Svensson, Emma; Segall, Thomas et al.

Ingår i Journal of immunotherapy (1997), s. 350-358, 2013

• DOI för Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma

Enhanced proliferation and tyrosine kinase pathway engagement in 4-1BB domain-containing CAR T cells

Karlsson, H.; Svensson, E.; Lindqvist, C.; Hambardzumyan, K. et al.

Ingår i Human Gene Therapy, 2013

AdCD40L immunostimulatory gene therapy shifts the MDSC- and macrophage profiles and promotes T cell infiltration in the tumor microenvironment

Liljenfeldt, Lina; Svensson, E.; Huang, H.; Dieterich, L. et al.

Ingår i Human Gene Therapy, 2013

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery

Fransson, Moa; Piras, Elena; Burman, Joachim; Nilsson, Berith et al.

Ingår i Journal of Neuroinflammation, s. 112, 2012

• DOI för CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
• Ladda ner fulltext (pdf) av CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

Dias, J D; Hemminki, O; Diaconu, I; Hirvinen, M et al.

Ingår i Gene Therapy, s. 988-998, 2012

• DOI för Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus

Diaconu, Iulia; Cerullo, Vincenzo; Hirvinen, Mari L M; Escutenaire, Sophie et al.

Ingår i Cancer Research, s. 2327-2338, 2012

• DOI för Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus

Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

Lindqvist, Camilla; Christiansson, Lisa; Thörn, Ingrid; Mangsbo, Sara et al.

Ingår i Immunology, s. 296-306, 2011

• DOI för Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

Genetically Engineered Cells Target CNS and Cure Experimental Autoimmune Encephalomyelitis

Fransson, Moa; Piras, Elena; Wang, H; Rasmussen Duprez, I et al.

Ingår i Human Gene Therapy, s. 1381-1381, 2010

• DOI för Genetically Engineered Cells Target CNS and Cure Experimental Autoimmune Encephalomyelitis

AdCD40L Immunogene Therapy for Bladder Carcinoma: The First Phase I/IIa Trial

Malmström, Per-Uno; Loskog, Angelica S. I.; Lindqvist, Camilla A.; Mangsbo, Sara M. et al.

Ingår i Clinical Cancer Research, s. 3279-3287, 2010

• DOI för AdCD40L Immunogene Therapy for Bladder Carcinoma: The First Phase I/IIa Trial

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

Mangsbo, Sara; Sandin, Linda; Anger, Kerstin; Korman, Alan et al.

Ingår i Journal of immunotherapy (1997), s. 225-235, 2010

• DOI för Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Lindqvist, Camilla A.; Christiansson, Lisa H.; Simonsson, Bengt; Enblad, Gunilla et al.

Ingår i Immunology, s. 371-376, 2010

• DOI för T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

T regulatory cells lacking CD25 are increased in MS during relapse

Fransson, Moa; Burman, Joachim; Lindqvist, Camilla; Atterby, Christina et al.

Ingår i Autoimmunity, s. 590-597, 2010

• DOI för T regulatory cells lacking CD25 are increased in MS during relapse

The T-cell pool is anergized in patients with multiple sclerosis in remission

Fransson, Moa; Liljenfeldt, Lina S.; Fagius, Jan; Tötterman, Thomas et al.

Ingår i Immunology, s. 92-101, 2009

• DOI för The T-cell pool is anergized in patients with multiple sclerosis in remission

Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

Vikman, Sofia; Sommaggio, Roberta; De La Torre, Manuel; Öberg, Kjell et al.

Ingår i Acta Oncologica, s. 391-400, 2009

• DOI för Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
• Ladda ner fulltext (pdf) av Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition

Lindqvist, Camilla; Sandin, Linda; Fransson, Moa; Loskog, Angelica

Ingår i Journal of immunotherapy (1997), s. 785-792, 2009

Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas

Vardouli, Lina; Lindqvist, Camilla; Vlahou, Katerina; Loskog, Angelica et al.

Ingår i Cancer Gene Therapy, s. 848-860, 2009

• DOI för Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas

Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma

von Euler, Henrik; Sadeghi, Arian; Carlsson, Björn; Rivera, Patricio et al.

Ingår i Journal of immunotherapy (1997), s. 377-384, 2008

• DOI för Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma

CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity

Mangsbo, Sara M; Ninalga, Christina; Essand, Magnus; Loskog, Angelica et al.

Ingår i Journal of immunotherapy (1997), s. 34-42, 2008

• DOI för CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity

CpG oligonucleotides demonstrate increased therapeutic efficacy compared to BCG in an aggressive orthotopic bladder cancer model

Ninalga, Christina; Mangsbo, Sara; Loskog, Angelica; Essand, Magnus et al.

Ingår i Journal of immunotherapy (1997), s. 34-42, 2008

• DOI för CpG oligonucleotides demonstrate increased therapeutic efficacy compared to BCG in an aggressive orthotopic bladder cancer model

Enhanced CD28 signaling may be a common mechanism underlying resistance to regulation - Reply

Loskog, Angelica; Brenner, M. K.

Ingår i Leukemia, s. 175-175, 2007

• DOI för Enhanced CD28 signaling may be a common mechanism underlying resistance to regulation - Reply

Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines

Loskog, Angelica; Ninalga, Christina; Paul-Wetterberg, Gabriella; de la Torre, Manuel et al.

Ingår i Journal of Urology, s. 353-358, 2007

• DOI för Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines

CD40L - a multipotent molecule for tumor therapy

Loskog, Angelica; Tötterman, Thomas

Ingår i Endocrine, metabolic & immune disorders - drug targets, s. 23-28, 2007

• DOI för CD40L - a multipotent molecule for tumor therapy

Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors

Loskog, Angelica; Ninalga, Christina; Tötterman, Thomas H.

Ingår i Cancer Immunology and Immunotherapy, s. 588-597, 2006

• DOI för Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors

Adenovirus-Mediated CD40 Ligand Therapy Induces Tumor Cell Apoptosis and Systemic Immunity in the TRAMP-C2 Mouse Prostate Cancer Model

Dzojic, Helena; Loskog, Angelica; Tötterman, Thomas H.; Essand, Magnus

Ingår i The Prostate, s. 831-838, 2006

• DOI för Adenovirus-Mediated CD40 Ligand Therapy Induces Tumor Cell Apoptosis and Systemic Immunity in the TRAMP-C2 Mouse Prostate Cancer Model

Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

Loskog, Angelica; Giandomenico, Valeria; Rossig, C.; Pule, M. et al.

Ingår i Leukemia, s. 1819-1828, 2006

• DOI för Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy

Loskog, Angelica; Ninalga, Christina; Hedlund, Titti; Alimohammadi, Mohammad et al.

Ingår i Laboratory Animals, s. 384-393, 2005

• DOI för Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy

CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer

Ninalga, Christina; Loskog, Angelica; Klevenfeldt, Magdalena; Essand, Magnus et al.

Ingår i Journal of immunotherapy (1997), s. 20-27, 2005

The immunotherapy of prostate and bladder cancer

Tötterman, Thomas H.; Loskog, Angelica; Essand, Magnus

Ingår i BJU International, s. 728-735, 2005

• DOI för The immunotherapy of prostate and bladder cancer

AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model

Loskog, Angelica S.; Fransson, Moa E.; Tötterman, Thomas H.

Ingår i Clinical Cancer Research, s. 8816-8821, 2005

• DOI för AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model

Adenovirus CD40 Ligand Gene Therapy Counteracts Immune Escape Mechanisms in the Tumor Microenvironment

Loskog, Angelica; Dzojic, Helena; Vikman, Sofia; Ninalga, Christina et al.

Ingår i Journal of Immunology, s. 7200-7205, 2004

Human urinary bladder carcinomas express adenovirus attachment and internalization receptors

Loskog, Angelica; Hedlund, Titti; Wester, Kenneth; de la Torre, Manuel et al.

Ingår i Gene Therapy, s. 547-553, 2002

• DOI för Human urinary bladder carcinomas express adenovirus attachment and internalization receptors

In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154

Loskog, Angelica; Tötterman, Thomas H.; Böhle, Andreas; Brandau, Sven

Ingår i Cancer Gene Therapy, s. 846-853, 2002

The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses

Labani-Motlagh, Alireza; Ashja-Mahdavi, Mehrnoush; Loskog, Angelica S.

Ingår i Frontiers in Immunology, 2020

• DOI för The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
• Ladda ner fulltext (pdf) av The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses

CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma

Enblad, Gunilla; Karlsson, Hannah; Loskog, Angelica S. I.

Ingår i Human Gene Therapy, s. 498-505, 2015

• DOI för CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma

Genetically engineered T cells for the treatment of cancer

Essand, Magnus; Loskog, Angelica S I

Ingår i Journal of Internal Medicine, s. 166-181, 2013

• DOI för Genetically engineered T cells for the treatment of cancer

T Regulatory Cells in B-Cell Malignancy: Tumor Support or Kiss of Death?

Lindqvist, Camilla A; Loskog, Angelica Si

Ingår i Immunology, s. 255-260, 2012

• DOI för T Regulatory Cells in B-Cell Malignancy: Tumor Support or Kiss of Death?

AdCD40L: Crossing the Valley of Death?

Ullenhag, Gustav; Loskog, Angelica S I

Ingår i International Reviews of Immunology, s. 289-298, 2012

• DOI för AdCD40L: Crossing the Valley of Death?

The Janus faces of CD40 in cancer

Loskog, Angelica; Eliopoulos, Aristides

Ingår i Seminars in Immunology, s. 301-307, 2009

• DOI för The Janus faces of CD40 in cancer

Genetic engineering - a new era for cancer immunotherapy?

Loskog, Angelica; Tötterman, Thomas H.

Ingår i Current Cancer Therapy Reviews, s. 194-198, 2007

Nya fotspår

Loskog, Angelica

Ingår i Skor är huvudsaken, s. 20-21, Uppsala universitet, 2013

Genetic engineering for cancer immunotherapy

Loskog, Angelica

Ingår i Gene Therapy and Cancer Research Focus, Nova Biomedical Books, 2008

CD40L-based cancer therapy: Expert commentary

Loskog, Angelica; Eliopoulos, Aris

Ingår i New Gene Therapy and Cancer Research, Nova Biomedical Books, 2008

Imatinib or dasatinib treatment of chronic myeloid leukemia reduces circulating myeloid-derived suppressor cells but increases their CD40 expression

Christiansson, Lisa; Söderlund, Stina; Hjorth-Hansen, Henrik; Höglund, Martin et al.

A Comparison of Multiplex Platforms for Absolute and Relative Protein Quantification

Christiansson, Lisa; Mustjoki, Satu; Loskog, Angelica S I; Mangsbo, Sara

Human Mesenchymal stromal cells expressing a CNS-targeting receptor can be administrated intra nasally and cure expersimental autoimmune enchphlomyelitis

Fransson, Moa; Piras, E; Wang, H; Burman, Joachim et al.

Engineered T regulatory cells target CNS and suppress active EAE upon intra nasal delivery

Fransson, Moa; Piras, E; Wang, H; Burman, Joachim et al.

Safety of intratumoral immunostimulatory LOAd703 gene therapy in patients with advanced cancer

Irenaeus, Sandra; Wenthe, Jessica; Eriksson, Emma; Schiza, Aglaia et al.

Single-cell RNA analysis reveal subpopulations of CAR T cells correlating with response in lymphoma patients

Sarén, Tina; Ramachandran, Mohanraj; Gammelgård, Gustav; Lövgren, Tanja et al.

Immunological evaluation of immunostimulatory gene therapy targeting CD40/4-1BB in advanced cancer patients (LOKON002)

Wenthe, Jessica; Eriksson, Emma; Naseri, Sedigheh; Sandin, Linda et al.

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Moreno, Rafael et al.

LOAd703 Gene Engineering Induces Tumor Cell Immunogenicity and Enhances the Effect of Chemotherapy in Ovarian Cancer Models

Naseri, Sedigheh; Härdin, Jonas; Mejia Cordova, Mariela; Eriksson, Emma et al.